

DAFTAR PUSTAKA

1. Cancer Council. Understanding Lung Cancer. Bell J, editor. Sydney: Cancer Council Australia; 2014. 9–11 p.
2. Lungusa. State of Lung Disease in Diverse Communities. American Lung Association. New York: American Lung Association; 2010.
3. Lukeman JM. What is Lung Cancer. Texas: University of Texas System Cancer Center. 2015. p. 30-40.
4. World Health Organization. The Global Cancer Observatory: Indonesia. International Agency of Research on Cancer; 2020;858:1–2.
5. Yunawan A. Klasifikasi Dan Epidemiologi Kanker Paru. 2014;
6. Hudoyo A, Wibawanto A, Lutfi A, Rima A, Putra AC, Ratnawati A, et al. Panduan Pelaksanaan Kanker Paru. Kementerian Kesehatan Republik Indonesia; 2016. p. 1-33.
7. Hulma MA, Basyar M, Mulyani H. Hubungan Karakteristik Penderita dengan Gambaran Sitopatologi pada Kasus Karsinoma Paru yang Dirawat di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2014;3(2):196–201.
8. Pipkra. Mengoptimalkan Manajemen Kanker Paru. *Farmacia*. 2012; 2.
9. World Health Organization. The Global Cancer Observatory: World. 2020;419:7–8.
10. Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and Molecular Classification of Lung Cancer. 1995. p. 34–43.
11. Oxnard GR, Nguyen KSH, Costa DB. Germline Mutations in Driver Oncogenes and Inherited Lung Cancer Risk Independent of Smoking History. *Journal of National Cancer Institute*. 2014;106(1):2013–5.
12. Jorge SEDC, Kobayashi SS, Costa DB. Epidermal Growth Factor Receptor (EGFR) Mutations in Lung Cancer: Preclinical and Clinical Data. *Brazilian Journal of Medical and Biological Research*. 2014;47(11):929–39.
13. Ahn MJ, Aisner DL, Dacic S, Horn Leora, Illei PB, Ishikawa Y, et al.

- IASLC Atlas of EGFR Testing in Lung Cancer. International Association for the Study of Lung Cancer. Florida: Editorial Rx Press; 2013. 79 p.
14. Asrul HH. Hubungan Berbagai Karakteristik Penderita Adenokarsinoma Paru Dengan Status Mutasi Epidermal Growth Factor Receptor (EGFR) di RSUP Haji Adam Malik Medan Tahun 2015 - 2017. Skripsi. Universitas Sumatera Utara; 2018.
 15. Yoon HY, Ryu JS, Sim YS, Kim D, Lee SY, Choi J, et al. Clinical Significance of EGFR Mutation Types in Lung Adenocarcinoma: A multi-Centre Korean Study. *Plos One*. 2020;15(2):1–14.
 16. Cappuzzo F. Guide to Targeted Therapies: EGFR Mutations in NSCLC. Switzerland: Springer International Publishing; 2014. 67 p.
 17. Pallis AG, Syrigos KN. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in The Treatment of NSCLC. *Lung Cancer*. 2013;80(2):120–30.
 18. Drake RL, Vogl W, Mitchell AWM. Gray's Basic Anatomy. Livingstone C, editor. Philadelphia; 2012.
 19. Gartner LP, Hiatt JL. Color TextBook of Histology. 3rd ed. Philadelphia: Saunders; 2007. p. 345 -365.
 20. Mescher AL. Histologi Dasar Junqueira. Edisi 12. H. Huriawati, editor. EGC; 2012. p. 292 - 308.
 21. Eroschenko VP. Atlas Histologi diFiore dengan Korelasi Fungsional. Edisi 11. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 333 - 354.
 22. Putriani FA. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru dengan Mutasi EGFR dan Non Mutasi EGFR. Skripsi. Semarang: Universitas Diponegoro; 2018.
 23. Kartini DS. Analisis Kadar Tumor Necrosis Factor Alpha (TNF- α) Cairan Bilasan Bronkus Pada Pasien Kanker Paru. Skripsi. Makassar: Universitas Hasanuddin; 2018.
 24. Perhimpunan Dokter Paru Indonesia. Kanker Paru: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Buku Ajar Paru. 2003;125–43.
 25. American Cancer Society. Lung cancer: Cancer Facts & Figures. Atlanta:

- American Cancer Society; 2015.
26. Putra MA. Karakteristik Penderita Kanker Paru Di Rumah Sakit Wahidin Sudirohusodo Makassar Periode Januari - Desember 2016. Skripsi. Makassar: Universitas Hasanuddin; 2017.
 27. Yunus M. Analisis Mutasi Gen Epidermal Growth Factor Receptor Pada Sampel Sediaan Hapusan Sitologi dan Plasma Darah Pasien Kanker Paru. Skripsi. Bogor: Institut Pertanian Bogor; 2017.
 28. Ilyas M. Gambaran Radiologi Toraks Pasien Tumor Paru di RSUP Dr. Wahidin Sudirohusodo. Skripsi. Makassar: Universitas Hasanuddin; 2017.
 29. Oliver J. Robbins Basic Pathology 9th Edition. Vol. 53, Journal of Chemical Information and Modeling. 2013. 1689–1699 p.
 30. Travis WD, Brambilla E, Müller-Hermelink K, Harris CC. Pathology & Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Edisi 3. IARC Publications; 2004;9-122.
 31. Sutandyo N, Suratman E. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia. Acta Med Indones. 2018;50(4):291–8.
 32. Handayani B. Diagnosa Kanker Paru Menggunakan Model Fuzzy. Vol. 1. Skripsi. Yogyakarta: Universitas Negeri Yogyakarta; 2014.
 33. Hernowo BS. Karsinoma Paru. Bandung Integrated Respiratory Care; 2012;1–10.
 34. The Armed Forces Institute of Pathology. Adenocarcinoma of The Lung. 2008. [Cited 2020 December 23], Available from http://peir2.path.uab.edu/pdl/dbra.cgi?uid=default&view_
 35. Lee SJ, Lee HS, Choi JS, Na JO, Seo KH, Oh MH, et al. Photomicroscopic Finding of Lepidic Predominant Adenocarcinoma. 2012. [Cited 2020 December 23], Available from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376882/>
 36. Adiatma. Hubungan Antara Karsinoma Paru Dengan Efusi Pleura. Skripsi. Semarang: Universitas Diponegoro; 2012.
 37. Davidson MR, Gazdar AF, Clarke BE. The Pivotal Role of Pathology in

- The Management of Lung Cancer. Vol. 5, Journal of Thoracic Disease. 2013;5(S5):S463-S478.
38. Putriani FA. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru Dengan Mutasi EGFR dan Non Mutasi EGFR (Bab 1). Skripsi. Semarang: Universitas Diponegoro; 2018.
 39. International Association for the Study of Lung Cancer. Staging Handbook in Thoracic Oncology. 2nd ed. Rami-Porta R, editor. Florida: Editorial Rx Press; 2017. 184 p.
 40. Subuh M, Sulistyowati LS. Pedoman Pengendalian Faktor Risiko Kanker Paru. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018. 1–14 p.
 41. Nasional KPK. Kanker Paru. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017. 1–75 p.
 42. Nasional KPK. Panduan Penatalaksanaan Kanker Paru. Jakarta: Kementerian Kesehatan Republik Indonesia; 2019. 1–29 p.
 43. Putriani FA. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru Dengan Mutasi EGFR dan Non Mutasi EGFR (Bab II). Skripsi. Semarang: Universitas Diponegoro; 2018.
 44. Puspawati PR, Kristina SA, Wiedyaningsih C. Dampak Merokok Terhadap Kematian Dini Akibat Kanker di Indonesia: Estimasi Years of Life Lost (YLL). *Majalah Farmaseutik*. 2019;16(1):101–6.
 45. Massarelli E, Varella-garcia M, Tang X, Massarelli E, Varella-garcia M, Tang X et al. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non – Small-Cell Lung Cancer. *Clin Cancer Res*. 2007;13(10).
 46. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. *The New England Journal of Medicine*. Boston: Massachusetts Medical Society; 2009. 859-867 p.
 47. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD et al. Epidermal Growth Factor Receptor Expression Status in Lung Cancer

- Correlates With Its Mutation. *Human Pathology*. 2005;36(10):1127-34.
48. Zamay TN, Zamay GS, Kolovskaya OS, Zukov RA, Petrova MM, Gargaun A, et al. Current and Prospective Protein Biomarkers of Lung Cancer Cancers. *Cancers*. 2017;9(11):1-22.
 49. Xu XW, Weng XH, Wang CL, Lin WW, Liu AL, Chen W, et al. Detection EGFR Exon 19 Status of Lung Cancer Patients by DNA Electrochemical Biosensor. *Biosensors and Bioelectronics*. 2016;80:411-7.
 50. Chan BA, Hughes BGM. Targeted Therapy for Non-Small Cell Lung Cancer: Current Standards and The Promise of The Future. *Translational Lung Cancer Research*. 2015;4(1):36-54.
 51. Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, et al. Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. *World Journal of Gastroenterology*. 2016;22(28):6345-61.
 52. Elhidsi M, Andarini SL, Hudoyo A. Profil Mutasi Epidermal Growth Factor Receptor Pasien Adenokarsinoma Paru Usia Muda. *Journal Respiratory Indonesia*. 2016;36(4):244-8.
 53. Mitsudomi T, Kosaka T, Yatabe Y. Biological and Clinical Implications of EGFR Mutations in Lung Cancer. *International Journal of Clinical Oncology*. 2006;11(3):190-8.
 54. Nuraini P. Faktor Risiko Kanker Paru Di RSUP Persahabatan Jakarta Tahun 2009-2010. Skripsi. Jakarta: Universitas Islam Negeri Syarif Hidayatullah; 2011.
 55. De Groot PM, Wu CC, Carter BW, Munden RF. The Epidemiology of Lung Cancer. *Translational Lung Cancer Research*. 2018;7(3):220-33.
 56. Ueno T, Toyooka S, Suda K, Soh J, Yatabe Y, Miyoshi S, et al. Impact of Age on Epidermal Growth Factor Receptor Mutation in Lung Cancer. *Lung Cancer*. 2012;78(3):207-11.
 57. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, et al. Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis. *Clinical Cancer Research*.

- 2012;18(7):1947–53.
58. Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR, Kim CH, et al. Association Between Age At Diagnosis and The Presence of EGFR Mutations in Female Patients With Resected Non-Small Cell Lung Cancer. *J Thorac Oncol.* 2010;5(12):1949–52.
 59. Ferrini RL, Barrett-Connor E. Sex Hormones and Age: A Cross-Sectional Study of Testosterone and Estradiol and Their Bioavailable Fractions in Community-Dwelling Men. *American Journal of Epidemiology.* 1998;147(8):750–4.
 60. Gray A, Feldman HA, Mckinlay JB, Longcope C. Age, Disease, and Changing Sex Hormone Levels in Middle-Aged Men: Results of the Massachusetts Male Aging Study. *Journal of Clinical Endocrinology Metabolism.* 1991;73(5):1016–25.
 61. Leifke E, Gorenoi V, Wichers C, Von Zur Mühlen A, Von Büren E, Brabant G. Age-Related Changes of Serum Sex Hormones, Insulin-Like Growth Factor-1 and Sex-Hormone Binding Globulin Levels in Men: Cross-sectional Data From A Healthy Male Cohort. *Clinical Endocrinology (Oxf).* 2000;53(6):689–95.
 62. Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, et al. Testosterone and Estradiol Among Older Men. *Journal of Clinical Endocrinology Metabolism.* 2006;91(4):1336–44.
 63. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, et al. The Influence of Aging on Plasma Sex Hormones in Men: The Telecom Study. *American Journal of Epidemiology.* 1992;135(7):783–91.
 64. O'Callaghan D, O'Donnell D, O'Connell F, O'Byrne KJ. The Role of Inflammation in the Pathogenesis of Non-Small Cell Lung Cancer. 2010;5(12):2024-36.
 65. Gaur P, Bhattacharya S, Kant S, Kushwaha RAS, Singh G, Pandey S. Association of Cytokines Levels with Epidermal Growth Factor Receptor Mutation in Lung Cancer Patients. *Journal of Cancer Research and Therapeutics.* 2020;16:811-5.

66. Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, et al. EGFR Mutation, Smoking, and Gender in Advanced Lung Adenocarcinoma. *Oncotarget*. 2017;8(58):98384-93.

